VolitionRx Reports Its Nu.Q Vet Assay Detects 2 Common Canine Cancers
Portfolio Pulse from Benzinga Newsdesk
VolitionRx has announced that its Nu.Q Vet Assay can detect two common canine cancers. This development could enhance the company's product offerings in veterinary diagnostics.
April 29, 2020 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VolitionRx's Nu.Q Vet Assay has demonstrated the ability to detect two common canine cancers, which could strengthen its position in the veterinary diagnostics market.
The announcement of the Nu.Q Vet Assay's ability to detect canine cancers is a positive development for VolitionRx, as it could enhance their product offerings and market position in veterinary diagnostics. This news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90